Core Viewpoint - Junshi Biosciences (688180) forecasts a net profit attributable to shareholders of approximately -870 million yuan for 2025, indicating a significant reduction in losses compared to the previous year, with a decrease of about 408 million yuan or 31.85% year-on-year [1] Group 1 - The company expects to report a net loss for 2025, but the loss amount is significantly narrowed compared to the same period last year [1] - The improvement in financial performance is attributed to the implementation of the "quality improvement and efficiency enhancement" action plan, which has notably enhanced commercial capabilities while strengthening cost control and resource focus [1] - During the reporting period, the company maintained efficient progress on its core pipeline while controlling expenses, advancing several innovative drugs with international market competitiveness, including JS207, JS212, and JS213 [1]

Core Viewpoint - Junshi Biosciences (01877) expects to achieve approximately 2.5 billion yuan in revenue for the year 2025, representing a year-on-year growth of about 28.32% [1] Financial Performance - The projected R&D expenses for 2025 are approximately 1.353 billion yuan, reflecting a year-on-year increase of about 6.10% [1] - The expected net loss attributable to the parent company for 2025 is around 873 million yuan, a reduction of approximately 31.85% compared to the previous year [1] - After excluding the impact of share-based payments, the net loss is projected to be about 799 million yuan, a decrease of approximately 37.62% year-on-year [1] - The net loss after excluding non-recurring gains and losses is expected to be around 985 million yuan, down about 23.64% year-on-year [1] - The net loss after excluding both share-based payments and non-recurring items is projected to be approximately 911 million yuan, a reduction of about 29.37% year-on-year [1] Product and Market Development - The increase in revenue is primarily due to the growth in sales of commercialized drugs, particularly the core product Toripalimab injection (brand name: Tuoyi®), which saw significant sales growth in the domestic market [1] - As of the announcement date, Tuoyi® has been approved for 12 indications in mainland China, all of which are included in the national medical insurance catalog, making it the only anti-PD-1 monoclonal antibody for treating renal cancer, triple-negative breast cancer, and melanoma in the catalog [1] - The company continues to expand its global commercialization network, with Toripalimab approved in over 40 countries and regions, including mainland China, Hong Kong, the United States, the EU, India, the UK, Jordan, Australia, Singapore, the UAE, Kuwait, Pakistan, Canada, and Bahrain [2] Strategic Initiatives - Despite the expected net loss, the company has significantly narrowed its loss compared to the previous year, mainly due to the implementation of the "quality improvement and efficiency enhancement" action plan, which has improved commercialization capabilities while strengthening cost control and resource focus [2] - The company is advancing its core pipeline efficiently while controlling expenses, rapidly progressing clinical trials for several innovative drugs with international market competitiveness, including JS207 (PD-1/VEGF dual antibody), JS212 (EGFR/HER3 ADC), and JS213 (PD-1/IL-2 fusion protein) [2] - JS207 is currently in Phase II clinical trials, exploring combinations with chemotherapy, monoclonal antibodies, ADCs, and other drugs across multiple tumor types, with ongoing Phase II trials for the combination of JS207 and JS212 [2] - The company aims to accelerate pipeline development and push more advantageous products and indications into the registration clinical trial phase as soon as possible [2]